0001193125-26-122774
SEC filingMaze Therapeutics reported fourth quarter and full year 2025 financial results with $360.0 million in cash supporting operations into 2028, announced positive Phase 2 HORIZON topline data for MZE829 showing 35.6% mean uACR reduction in broad AMKD patients, and appointed Neil Kumar as a Class I director effective March 27, 2026. These disclosures provide clinical proof-of-concept, financial visibility, and strengthened board expertise.